PBPhilippe Brasseur

Philippe Brasseur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Brasseur has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing Drivers of Full Adoption of Test and Treat Policy for Malaria in Senegal

    by Christina Faust, Jonathan Zelner, Philippe Brasseur, Michel Vaillant, Malick Badiane, Moustafa Cisse, Bryan Grenfell, Piero Olliaro

    Malaria treatment policy has changed from presumptive treatment to targeted “test and treat” (T&T) with malaria rapid diagnostic tests (RDTs) and artemisinin combination therapy (ACT). This transition involves changing behavior among health providers, meaning delays between introduction and full implementation are recorded in almost every instance. We investigated factors affecting successful transition, and suggest approaches for accelerating uptake of T&T. Records from 2000 to 2011 from health clinics in Senegal where malaria is mesoendemic were examined (96,166 cases). The study period encompassed the implementation of national T&T policy in 2006. Analysis showed that adherence to test results is the first indicator of T&T adoption and is dependent on accumulation of experience with positive RDTs (odds ratio [OR]: 0.55 [P ≤ 0.001], 95% confidence interval [CI]: 0.53–0.58). Reliance on tests for malaria diagnosis (rather than presumptive diagnosis) followed after test adherence is achieved, and was also associated with increased experience with positive RDTs (OR: 0.60 [P ≤ 0.001], 95% CI: 0.58–0.62). Logistic models suggest that full adoption of T&T clinical practices can occur within 2 years, that monitoring these behavioral responses rather than RDT or ACT consumption will improve evaluation of T&T uptake, and that accelerating T&T uptake by focusing training on adherence to test results will reduce overdiagnosis and associated health and economic costs in mesoendemic regions.


  • Open Access

    Malaria elimination in Haiti by the year 2020: an achievable goal?

    by Paul Jacques Boncy, Paul Adrien, Jean Frantz Lemoine, Alexandre Existe, Patricia Jean Henry, Christian Raccurt, Philippe Brasseur, Natael Fenelon, John B Dame, Bernard A Okech, et al.

    Haiti and the Dominican Republic, which share the island of Hispaniola, are the last locations in the Caribbean where malaria still persists. Malaria is an important public health concern in Haiti with 17,094 reported cases in 2014. Further, on January 12, 2010, a record earthquake devastated densely populated areas in Haiti including many healthcare and laboratory facilities. Weakened infrastructure provided fertile reservoirs for uncontrolled transmission of infectious pathogens. This situation results in unique challenges for malaria epidemiology and elimination efforts. To help Haiti achieve its malaria elimination goals by year 2020, the Laboratoire National de Santé Publique and Henry Ford Health System, in close collaboration with the Direction d’Épidémiologie, de Laboratoire et de Recherches and the Programme National de Contrôle de la Malaria, hosted a scientific meeting on “Elimination Strategies for Malaria in Haiti” on January 29-30, 2015 at the National Laboratory in Port-au-Prince, Haiti. The meeting brought together laboratory personnel, researchers, clinicians, academics, public health professionals, and other stakeholders to discuss main stakes and perspectives on malaria elimination. Several themes and recommendations emerged during discussions at this meeting. First, more information and research on malaria transmission in Haiti are needed including information from active surveillance of cases and vectors. Second, many healthcare personnel need additional training and critical resources on how to properly identify malaria cases so as to improve accurate and timely case reporting. Third, it is necessary to continue studies genotyping strains of Plasmodium falciparum in different sites with active transmission to evaluate for drug resistance and impacts on health. Fourth, elimination strategies outlined in this report will continue to incorporate use of primaquine in addition to chloroquine and active surveillance of cases. Elimination of malaria in Haiti will require collaborative multidisciplinary approaches, sound strategic planning, and strong ownership of strategies by the Haiti Ministère de la Santé Publique et de la Population.


  • Évolution de la prévalence du paludisme et de la prise en charge des fièvres de 2000 et 2012 en Casamance, Sénégal

    by P. Brasseur, C. Raccurt, M. Badiane, M. Cissé, J.-F. Trape, C. Sokhna

    Avant 2006 au Sénégal toute fièvre sans diagnostic biologique était considérée a priori comme un paludisme et traitée par la chloroquine. De 2004 à 2006, devant la progression de la résistance de Plasmodium falciparum au traitement par la chloroquine, le traitement par l’association amodiaquine/sulfadoxine-pyriméthamine a été recommandé. A partir de 2006, on a assisté au niveau national à l’introduction des tests de diagnostic rapide (TDR) et en 2007 à la recommandation du traitement par l’association artesunate-amodiaquine (ASAQ). Ceci a coïncidé avec une diminution de la prévalence des cas de paludisme et un changement de comportement pour la prise en charge des fièvres. A Mlomp en Casamance, les examens microscopiques de sang (frottis et gouttes épaisses) étaient effectués systématiquement depuis 1995 chez les patients fébriles présentant des signes cliniques évocateurs de paludisme et le traitement par ASAQ était effectué à titre expérimental. Entre 2000 et 2012, 70 892 patients ont consulté au dispensaire, dont 51,2 % pour une fièvre. Parmi ces cas de fièvre, 72,4 % étaient suspects de paludisme et 27,6 % étaient dus à des infections virales ou bactériennes. Le nombre de cas de paludisme confirmé a diminué progressivement de 1 365 en 2000 à 53 en 2012. Si l’on compare la période 2000–2006 à 2007–2012 on constate que le nombre de cas de fièvre a diminué de moitié, le nombre de cas de fièvres identifiées à d’autres causes que le paludisme a doublé et le nombre de traitements antipaludiques a diminué de 86 %. L’amélioration de la prise en charge des fièvres à Mlomp s’est traduite par une meilleure identification des causes et une diminution importante de traitements antipaludiques inappropriés. Before 2006 in Senegal, in the absence of clinical diagnosis, all fever cases were considered as malaria and treated with chloroquine. Between 2004–2006, to face the dramatic increase of Plasmodium falciparum resistance to chloroquine, the combination of amodiaquine plus sulfadoxine-pyriméthamine was recommended for treatment. In 2006, rapid diagnostic tests were introduced and the treatment with a combination of artesunate plus amodiaquine (ASAQ) became the national recommendation for malaria treatment in 2007. This coincided with a decrease of the prevalence of malaria cases and change in fever management. Since 1995 in Mlomp in Casamance, thin and thick blood smear examination has systematically been done in patients with fever and clinical signs of malaria, and treatment with ASAQ given as experimental procedure. Between 2000 and 2012, 70,892 outpatients were attending the health center, and 51.2% of them for fever. Among these fever cases, 72.4% were suspected of malaria and 27.6% were identified as bacterial and viral infections. Confirmed malaria cases decreased dramatically from 1365 in 2000 to 53 in 2012. While comparing the 2 periods 2000–2006 and 2007–2012, the number of fever cases decreased by half, the number of fever identified as non malaria doubled and malaria treatment given decreased by 86%. Improvement of fever management in Mlomp has contributed to a better identification of their cause and to a decrease of inappropriate malaria treatments.


  • Open Access

    Use of a colorimetric (DELI) test for the evaluation of chemoresistance of Plasmodium falciparum and Plasmodium vivax to commonly used anti-plasmodial drugs in the Brazilian Amazon

    by Lilian R Pratt-Riccio, Yonne F Chehuan, Maria José Siqueira, Maria das Graças Alecrim, Cesare Bianco-Junior, Pierre Druilhe, Philippe Brasseur, Maria de Fátima Ferreira-Da-Cruz, Leonardo Jm Carvalho, Cláudio T Daniel-Ribeiro

    Background: The emergence and spread of Plasmodium falciparum and Plasmodium vivax resistance to available anti-malarial drugs represents a major drawback in the control of malaria and its associated morbidity and mortality. The aim of this study was to evaluate the chemoresistance profile of P. falciparum and P. vivax to commonly used anti-plasmodial drugs in a malaria-endemic area in the Brazilian Amazon. Methods: The study was carried out in Manaus (Amazonas state), in the Brazilian Amazon. A total of 88 P. falciparum and 178 P. vivax isolates was collected from 2004 to 2007. The sensitivity of P. falciparum isolates was determined to chloroquine, quinine, mefloquine and artesunate and the sensitivity of P. vivax isolates was determined to chloroquine and mefloquine, by using the colorimetric DELI test. Results: As expected, a high prevalence of P. falciparum isolates resistant to chloroquine (78.1%) was observed. The prevalence of isolates with profile of resistance or decreased sensitivity for quinine, mefloquine and artesunate was 12.7, 21.2 and 11.7%, respectively. In the case of P. vivax, the prevalence of isolates with profile of resistance for chloroquine and mefloquine was 9.8 and 28%, respectively. No differences in the frequencies of isolates with profile of resistance or geometric mean IC50s were seen when comparing the data obtained in 2004, 2005, 2006 and 2007, for all tested anti-malarials. Conclusions: The great majority of P. falciparum isolates in the Brazilian malaria-endemic area remain resistant to chloroquine, and the decreased sensitivity to quinine, mefloquine and artesunate observed in 10–20% of the isolates must be taken with concern, especially for artesunate. Plasmodium vivax isolates also showed a significant proportion of isolates with decreased sensitivity to chloroquine (first-line drug) and mainly to mefloquine. The data presented here also confirm the usefulness of the DELI test to generate results able to impact on public health policies.


  • Open Access

    Changing patterns of malaria during 1996-2010 in an area of moderate transmission in Southern Senegal

    by Philippe Brasseur, Malick Badiane, Moustafa Cisse, Patrice Agnamey, Michel T Vaillant, Piero L Olliaro

    Background: Malaria is reportedly receding in different epidemiological settings, but local long-term surveys are limited. At Mlomp dispensary in south-western Senegal, an area of moderate malaria transmission, year-round, clinically-suspected malaria was treated with monotherapy as per WHO and national policy in the 1990s. Since 2000, there has been a staggered deployment of artesunate-amodiaquine after parasitological confirmation; this was adopted nationally in 2006. Methods: Data were extracted from clinic registers for the period between January 1996 and December 2010, analysed and modelled. Results: Over the 15-year study period, the risk of malaria decreased about 32-times (from 0.4 to 0.012 episodes person-year), while anti-malarial treatments decreased 13-times (from 0.9 to 0.07 treatments person-year) and consultations for fever decreased 3-times (from 1.8 to 0.6 visits person-year). This was paralleled by changes in the age profile of malaria patients so that the risk of malaria is now almost uniformly distributed throughout life, while in the past malaria used to concern more children below 16 years of age. Conclusions: This study provides direct evidence of malaria risk receding between 1996-2010 and becoming equal throughout life where transmission used to be moderate. Infection rates are no longer enough to sustain immunity. Temporally, this coincides with deploying artemisinin combinations on parasitological confirmation, but other contributing causes are unclear.